# Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

> clinical trial · VERIFIED · 2026-07-31

Status: ACTIVE_NOT_RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Metastatic Esophageal Adenocarcinoma

- Company: National Cancer Institute (NCI)
- Sector: Metastatic Esophageal Adenocarcinoma
- Primary source: https://clinicaltrials.gov/study/NCT01142388

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.